Evidence map›Paper›PMID 33159804›Full record

ArticleJournal of gastroenterology2021

Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.

Luis García-Villarreal, Andrea Hernández-Ortega, Ana Sánchez-Monteagudo, Luis Peña-Quintana, Teresa Ramírez-Lorenzo, Marta Riaño, Raquel Moreno-Pérez, Alberto Monescillo, Daniel González-Santana, Ildefonso Quiñones and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epidemiology of Wilson's Disease and Pathogenic Variants of theInternational journal of molecular sciences · 2024
    Review
  6. Article
  7. Monitoring of Copper in Wilson Disease.Diagnostics (Basel, Switzerland) · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Luis García-VillarrealUnidad de Investigación, Complejo Hospitalario Universitario Insular Materno-Infantil, Avda Maritima del Sur, s/n, 35016, Las Palmas de Gran Canaria, Spain.
Andrea Hernández-OrtegaUnidad de Gastroenterología, Hepatología y Nutrición Pediátrica, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Ana Sánchez-MonteagudoUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Luis Peña-QuintanaUnidad de Gastroenterología, Hepatología y Nutrición Pediátrica, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Teresa Ramírez-LorenzoUnidad de Investigación, Complejo Hospitalario Universitario Insular Materno-Infantil, Avda Maritima del Sur, s/n, 35016, Las Palmas de Gran Canaria, Spain.
Marta RiañoDepartment of Clinical Biochemistry and Clinical Analyses, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Raquel Moreno-PérezDepartment of Nursery. Atencion Primaria, Las Palmas de Gran Canaria, Spain.
Alberto MonescilloDepartment of Gastroenterology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Daniel González-SantanaUnidad de Gastroenterología, Hepatología y Nutrición Pediátrica, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Ildefonso QuiñonesDepartment of Gastroenterology. Hospital, Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain.
Almudena Sánchez-VillegasDepartment of Public Health, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Vicente Olmo-QuintanaDepartment of Pharmacy, Atencion Primaria, Las Palmas de Gran Canaria, Spain.
Paloma Garay-SánchezUnidad de Investigación, Complejo Hospitalario Universitario Insular Materno-Infantil, Avda Maritima del Sur, s/n, 35016, Las Palmas de Gran Canaria, Spain.
Carmen EspinósUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Jesús M GonzálezUnidad de Investigación, Complejo Hospitalario Universitario Insular Materno-Infantil, Avda Maritima del Sur, s/n, 35016, Las Palmas de Gran Canaria, Spain.
Antonio TugoresUnidad de Investigación, Complejo Hospitalario Universitario Insular Materno-Infantil, Avda Maritima del Sur, s/n, 35016, Las Palmas de Gran Canaria, Spain. atugores@yahoo.com.ORCID http://orcid.org/0000-0002-1849-9239
Hospital Universitario Insular de Gran Canaria · ESCentro de Investigacion Principe Felipe · ESUniversidad de Las Palmas de Gran Canaria · ESGobierno de Canarias · ESHospital Universitario de Gran Canaria Doctor Negrín · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWilson disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene. An early diagnosis is crucial to prevent evolution of the disease, as implantation of early therapeutic measures fully prevents its symptoms. As population genetics data predict a higher than initially expected prevalence, it was important to define the basic diagnostic tools to approach population screening.

methodsA highly genetically homogeneous cohort of 70 patients, belonging to 50 unrelated families, has been selected as a framework to analyze all their clinical, biochemical and genetic characteristics, to define the disease in our population, with an estimated prevalence of 1 in 12,369, and determine the most useful features that reach diagnostic value.

resultsSerum ceruloplasmin below 11.5 mg/dL and cupremia below 60 μg/mL, were the best analytical predictors of the disease in asymptomatic individuals, while cupruria or hepatic copper determination were less powerful. Genetic analysis reached a conclusive diagnosis in all 65 patients available for complete testing. Of them, 48 were carriers of at least one p.Leu708Pro mutant allele, with 24 homozygotes. Nine patients carried a promoter deletion mutation, revealing that extended sequencing beyond the ATP7B gene-coding region is essential. All mutations caused hepatic damage since early ages, increasing its severity as diagnosis was delayed, and neurological symptoms appear.

conclusionSerum ceruloplasmin determination followed by genetic screening would reduce costs and favor the prioritization of non-invasive procedures to reach a definitive diagnosis, even for asymptomatic cases.

Indexed as

AdolescentAdultAgedBiomarkersCeruloplasminChildChild, PreschoolCopperCopper-Transporting ATPasesDelayed DiagnosisEarly DiagnosisFemaleGenetic MarkersGenetic TestingHepatolenticular DegenerationHumansATP7B protein, humanBiomarkersCeruloplasminCopperCopper-Transporting ATPasesGenetic MarkersCeruloplasminGeneticsWilson disease

Identifiers

PMID33159804
OpenAlexW3097617893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.